# BoB@JPM: Brian Hilberdink, Boehringer Ingelheim

Page: https://stenobird.com/podcast/business-of-biotech-123501/bob-jpm-brian-hilberdink-boehringer-ingelheim
Text version: https://stenobird.com/podcast/business-of-biotech-123501/bob-jpm-brian-hilberdink-boehringer-ingelheim.md
Podcast: [Business Of Biotech](https://stenobird.com/podcast/business-of-biotech-123501)
Published: 2026-02-02T11:00:00+00:00
Episode link: https://www.buzzsprout.com/1011661/episodes/18584367-bob-jpm-brian-hilberdink-boehringer-ingelheim.mp3
Audio file: https://www.buzzsprout.com/1011661/episodes/18584367-bob-jpm-brian-hilberdink-boehringer-ingelheim.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/bob-jpm-brian-hilberdink-boehringer-ingelheim
Duration seconds: 2675

## Resource

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brian Hilberdink, President of U.S. Human Pharma at Boehringer Ingelheim, returns to the show during the J.P. Morgan Healthcare Conference, and following his departure from LEO Pharma (see episode 164). Brian talks about new opportunities in obesity, the benefits of private ownership in funding early science, Boehringer's deal strategy, using AI to improve commercialization efforts, and ...

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/bob-jpm-brian-hilberdink-boehringer-ingelheim/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/business-of-biotech-123501/bob-jpm-brian-hilberdink-boehringer-ingelheim.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.